[go: up one dir, main page]

MA50073A - Polythérapie de lasmiditan et d'un antagoniste du cgrp pour une utilisation dans le traitement de la migraine - Google Patents

Polythérapie de lasmiditan et d'un antagoniste du cgrp pour une utilisation dans le traitement de la migraine

Info

Publication number
MA50073A
MA50073A MA050073A MA50073A MA50073A MA 50073 A MA50073 A MA 50073A MA 050073 A MA050073 A MA 050073A MA 50073 A MA50073 A MA 50073A MA 50073 A MA50073 A MA 50073A
Authority
MA
Morocco
Prior art keywords
lasmiditan
polytherapy
migraine
treatment
cgrp antagonist
Prior art date
Application number
MA050073A
Other languages
English (en)
Inventor
Sheena Aurora
Kirk Willis Johnson
John Henry Krege
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA50073A publication Critical patent/MA50073A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA050073A 2017-09-06 2018-08-30 Polythérapie de lasmiditan et d'un antagoniste du cgrp pour une utilisation dans le traitement de la migraine MA50073A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762554726P 2017-09-06 2017-09-06

Publications (1)

Publication Number Publication Date
MA50073A true MA50073A (fr) 2020-07-15

Family

ID=63529021

Family Applications (2)

Application Number Title Priority Date Filing Date
MA050073A MA50073A (fr) 2017-09-06 2018-08-30 Polythérapie de lasmiditan et d'un antagoniste du cgrp pour une utilisation dans le traitement de la migraine
MA71474A MA71474A (fr) 2017-09-06 2018-08-30 Polythérapie de lasmiditan et d'un antagoniste du cgrp pour une utilisation dans le traitement de la migraine

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA71474A MA71474A (fr) 2017-09-06 2018-08-30 Polythérapie de lasmiditan et d'un antagoniste du cgrp pour une utilisation dans le traitement de la migraine

Country Status (17)

Country Link
US (1) US20200268735A1 (fr)
EP (2) EP3678665A1 (fr)
JP (5) JP6922092B2 (fr)
KR (2) KR20230025945A (fr)
CN (3) CN116059204A (fr)
AU (1) AU2018329568B2 (fr)
BR (1) BR112020002077A2 (fr)
CA (1) CA3073996C (fr)
EA (1) EA202090457A1 (fr)
IL (2) IL314347A (fr)
MA (2) MA50073A (fr)
MX (2) MX2020002554A (fr)
MY (1) MY205182A (fr)
SG (1) SG11202001387WA (fr)
TW (1) TWI754772B (fr)
WO (1) WO2019050759A1 (fr)
ZA (1) ZA202000443B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102753171A (zh) 2009-04-02 2012-10-24 科鲁西德制药公司 2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲酰胺的组合物
SMT201900293T1 (it) * 2011-05-20 2019-07-11 Alderbio Holdings Llc Composizioni comprendenti anticorpi anti-cgrp e loro utilizzo
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
HK1232218A1 (zh) 2014-02-05 2018-01-05 Merck Sharp & Dohme Llc Cgrp-活性化合物的片剂制剂
PL3551617T3 (pl) 2016-12-06 2021-12-20 Colucid Pharmaceuticals, Inc. Kompozycje i sposoby związane z pirydynoilopiperydynowymi agonistami 5-HT<sub>1F</sub>
TWI754772B (zh) * 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法
US20190374518A1 (en) * 2018-06-08 2019-12-12 Allergan Pharmaceuticals International Limited Treatment of migraine
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
TWI826514B (zh) 2018-09-04 2023-12-21 美商美國禮來大藥廠 用於預防偏頭痛之拉米迪坦(lasmiditan)長期夜間投藥
JP2022517433A (ja) * 2019-01-20 2022-03-08 バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッド 突出性の片頭痛を処置するためのｃｇｒｐアンタゴニスト
TWI776175B (zh) 2019-07-09 2022-09-01 美商美國禮來大藥廠 大規模製備2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺半琥珀酸鹽的方法及中間體，以及2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺醋酸鹽之製備
CA3190176A1 (fr) 2020-07-29 2022-02-03 Allergan Pharmaceuticals International Limited Traitement de migraine
AU2021409718A1 (en) 2020-12-22 2023-07-13 Allergan Pharmaceuticals International Limited Treatment of migraine
MX2024003952A (es) 2021-09-27 2024-05-27 Allergan Pharmaceuticals Int Ltd Combinación que comprende atogepant para tratar la migraña.
CN116270505A (zh) * 2021-12-20 2023-06-23 南京科默生物医药有限公司 含半琥珀酸拉司米地坦的口服固体制剂及其3d打印制备技术
JP7499538B1 (ja) 2023-03-29 2024-06-14 ロゴスサイエンス株式会社 慢性疼痛の治療、改善およびセルフケアシステム

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002353D0 (sv) * 2000-06-22 2000-06-22 Astrazeneca Ab New use
TWI263497B (en) 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
CA2545771A1 (fr) * 2003-11-12 2005-05-26 Nps Pharmaceuticals, Inc. Traitement de la migraine comportant des composes d'isovaleramide et des agonistes de la serotonine
CA2795062A1 (fr) * 2010-04-02 2011-10-06 Colucid Pharmaceuticals, Inc. Compositions et methodes de synthese d'agonistes des recepteurs 5-ht1f derives de la pyridinoylpiperidine
AR081434A1 (es) * 2010-06-10 2012-08-29 Lilly Co Eli Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
CA3036632A1 (fr) * 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Traitement de la migraine refractaire
US20190071490A1 (en) * 2017-03-02 2019-03-07 Beth Israel Deaconess Medical Center, Inc. Preventing Post-Ictal Headaches
TWI754772B (zh) * 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法

Also Published As

Publication number Publication date
JP7183355B2 (ja) 2022-12-05
NZ761634A (en) 2024-05-31
EP4397317A2 (fr) 2024-07-10
WO2019050759A1 (fr) 2019-03-14
TW201919624A (zh) 2019-06-01
JP7480261B2 (ja) 2024-05-09
US20200268735A1 (en) 2020-08-27
CN116509861A (zh) 2023-08-01
MY205182A (en) 2024-10-04
ZA202000443B (en) 2022-07-27
EP4397317A3 (fr) 2024-10-16
KR20200036919A (ko) 2020-04-07
JP2020530861A (ja) 2020-10-29
JP2021176884A (ja) 2021-11-11
MX2023008760A (es) 2023-08-02
JP7711255B2 (ja) 2025-07-22
SG11202001387WA (en) 2020-03-30
JP2023029872A (ja) 2023-03-07
MA71474A (fr) 2025-04-30
AU2018329568A1 (en) 2020-02-06
EA202090457A1 (ru) 2020-06-10
JP6922092B2 (ja) 2021-08-18
JP2024109585A (ja) 2024-08-14
BR112020002077A2 (pt) 2020-07-28
IL314347A (en) 2024-09-01
IL273031A (en) 2020-04-30
MX2020002554A (es) 2020-07-13
CN111032044A (zh) 2020-04-17
KR20230025945A (ko) 2023-02-23
CA3073996A1 (fr) 2019-03-14
EP3678665A1 (fr) 2020-07-15
CA3073996C (fr) 2022-05-31
JP2025165940A (ja) 2025-11-05
TWI754772B (zh) 2022-02-11
AU2018329568B2 (en) 2021-09-23
CN116059204A (zh) 2023-05-05

Similar Documents

Publication Publication Date Title
MA50073A (fr) Polythérapie de lasmiditan et d&#39;un antagoniste du cgrp pour une utilisation dans le traitement de la migraine
MA51032A (fr) Utilisation d&#39;antagonistes de fcrn pour le traitement de la myasthénie grave généralisée
EP3500299A4 (fr) Utilisation d&#39;une combinaison comprenant un inhibiteur de btk pour le traitement de cancers
EP3496666A4 (fr) Dispositifs et procédés pour le traitement d&#39;une insuffisance valvulaire
MA54609A (fr) Inhibiteurs aza-hétérobicycliques de mat2a et procédés d&#39;utilisation pour le traitement du cancer
MA54608A (fr) Inhibiteurs aza-hétérobicycliques de mat2a et procédés d&#39;utilisation pour le traitement du cancer
MA46836A (fr) Agents, utilisations et procédés pour le traitement d&#39;une synucléinopathie
EP3504187A4 (fr) Utilisation de la pridopidine pour le traitement du déclin fonctionnel
EP3463315A4 (fr) Compositions et méthodes d&#39;utilisation de nintédanib pour le traitement de maladies oculaires à néovascularisation anormale
EP3512517A4 (fr) Utilisation de pridopidine pour le traitement de l&#39;anxiété et de la dépression
EP3319534A4 (fr) Systèmes et procédés pour le traitement et la prévention d&#39;un dysfonctionnement pelvien féminin
MA49131A (fr) Utilisation d&#39;antagonistes de klk5 pour le traitement d&#39;une maladie
FR3079749B1 (fr) Utilisation d&#39;un peptide pour un traitement de l&#39;epiderme
EP3481393A4 (fr) Association d&#39;un antagoniste de pd-1 et d&#39;un inhibiteur du raf pour le traitement du cancer.
EP3308783A4 (fr) Utilisation d&#39;une composition pour la fabrication d&#39;un médicament dans le traitement de la sclérose latérale amyotrophique
EP3397262A4 (fr) Combinaison d&#39;inhibiteur de hdac et d&#39;anticorps anti-pd-l1 pour le traitement de cancer des ovaires
FR24C1053I2 (fr) Utilisation du delgocitinib pour le traitement de l&#39;eczéma des mains chronique
EP3493802A4 (fr) Utilisation d&#39;inhibiteurs de l&#39;activité mitochondriale pour le traitement de la leucémie myéloïde aiguë à mauvais pronostic
MA43825A (fr) Schémas posologiques pour le traitement d&#39;infections fongiques
EP3331962A4 (fr) Agents d&#39;inversion à fonction carbonyle pour latex eau-dans-huile et procédés d&#39;utilisation
EP3877402A4 (fr) Traitement combiné pour l&#39;hypertension résistante
EP3426254C0 (fr) Utilisation d&#39;inhibiteurs de braf pour le traitement de réactions cutanées
EP3848022C0 (fr) Agent thérapeutique pour utilisation dans le traitement d&#39;infections
EP3773221A4 (fr) Traitement pour l&#39;hydrocéphalie
EP3813870C0 (fr) Inhibiteur de ccr5 destiné à être utilisé dans le traitement du cancer